SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.81-4.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert K. who wrote (16384)11/1/2003 7:22:41 PM
From: Bluegreen   of 17367
 
Bob, most don't understand Psoriasis patient population. THere are probably several million out there that would be moderate or severe if they stopped there current EXPENSIVE terrible inconvenient and sometimes messy smelly treatments. I don't know about you but I would trade all of that in a second for a once a week subQ injection. Remember when Inderal first came out.......think what happened to all those people controlled on other meds. I think the biological market for Psoriasis will EASILY hit 5 to 7 billion in the next few years. Is Raptiva that expensive.......NOT when compared to frequent office visits to a specialist..........not to mention time off from work and interference in regard to work productivity. And ............THANK GOODNESS to the WELL INFORMED patient of nowadays DEMANDING the BEST THERAPY for themselves. Thank goodness for the hammer of malpractice if some patient unfriendly physician prescribes something not in the patient's best interests.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News